Neonode (NASDAQ:NEON) has signed "a technology development agreement with a leading tier-one printer OEM."
The touch sensor tech developer says it has already signed licensing deals with printer OEMs controlling over 40% of the market. H-P is a known licensee; there's some debate on just how lucrative the deal is.
Privately-held Boehringer Ingelheim commences patient enrollment in a Phase 3 clinical trial evaluating the safety and efficacy of nintedanib in patients with colorectal cancer refractory to standard treatments. The double-blind randomized, placebo-controlled study will enroll more that 750 patients at 150 sites worldwide.
At issue are charges of rigging Swiss franc Libor benchmark interest rates, and JPMorgan (NYSE:JPM), UBS, and Credit Suisse (NYSE:CS) will be collectively fined more than $115M, reports Reuters. Not being penalized is RBS thanks to its role as a whistleblower in the case.
JPMorgan is reportedly set to receive the biggest fine at about $89M.
Net income of $531M, or $1.28 per diluted share vs. $452M, or$ 0.90 per diluted share in the same quarter a year ago.
Total revenues grew 3.5% to $3.7B and operating income increased 14% to $772M, the highest quarterly operating income total in the Company's history. Organic revenues grew 3.5%, with North American and international growth of 4% and 3%, respectively.
Record operating margins of 20.9% increased 190 bps, with enterprise initiatives contributing 120 bps. All segments produced operating margin improvement, with five segments growing operating margins by more than 200 bps.
The Company is raising its full-year EPS guidance range to $4.57-$4.65 from $4.50-$4.62.
For Q4, the Company is forecasting EPS to be in a range of $1.07-$1.15, on 2-3% percent organic revenue growth. Total revenue growth in Q4 is projected to be flat due to currency translation effects.